1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Andarix Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Rhenium (Re 188 P2045, BAY86-5284) - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Unknown | Andarix Pharmaceuticals | 60 | 2004-01-01 | 2022-11-07 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Lung Neoplasms (1) · Neoplasm Recurrence, Local (1) · Small Cell Lung Carcinoma (1)
Rhenium (1)
United States (1)